Fresenius has issued a software release to address issues that could interrupt treatment with its Ivenix large volume pumps.

Fresenius Kabi warned healthcare providers in a Dec. 5 letter to stop using certain Ivenix large-volume pumps because of the risk that pneumatic valves installed in some devices could issue a pump ...

For the third time since 2022, when it purchased infusion pump maker Ivenix for $240 million, Fresenius Kabi has earned a Class I rating from the FDA for a recall of the Ivenix medication delivery ...

FDA has upgraded Fresenius Kabi’s voluntary recall of certain Ivenix Large Volume Pump (LVP) primary administration sets to Class I after the company identified a manufacturing defect that could cause ...

Less than a year after putting down $240 million to acquire of Ivenix and its sensor- and software-backed infusion pump, Fresenius Kabi is recalling more than 1,500 of them. The recall affects only ...

The early alert on Fresenius' device is part of a new pilot by the FDA to improve the timeliness around public communications over potentially high-risk device recalls. Image credit: Tada Images via ...

The U.S. FDA has announced a class I recall of Iveninx large-volume infusion pumps made by Fresenius Kabi USA of Lake Zurich, Ill., due to a mechanical issue with fluid valve pins that could cause the ...

Fresenius Kabi USA recalled 1,546 large infusion pumps in a Class I recall, the most serious type, because of a risk of leaking products entering the electrical system and shutting down the device.

U.S. authorities are warning healthcare entities of security flaws in certain Fresenius Kabi Agilia Connect Infusion Systems. U.S. government authorities have issued an advisory warning about remotely ...

LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi announced today the successful smart pump interoperability of its Ivenix Infusion System at Fort HealthCare, a regional health care provider in ...

Fresenius SE, the largest publicly listed health-care provider in Europe, is the leading bidder to acquire Pfizer Inc.’s pumps and devices business, which could fetch $1.5 billion to $2 billion, ...